<DOC>
	<DOCNO>NCT02291289</DOCNO>
	<brief_summary>This randomize , multi-center , active-controlled , open-label , parallel-group study investigate efficacy safety biomarker-driven maintenance treatment first-line metastatic colorectal cancer ( mCRC ) . Patients mCRC eligible entry , receive prior chemotherapy metastatic setting . The entire study duration anticipate approximately 6 year .</brief_summary>
	<brief_title>A Multi-Center Study Biomarker-Driven Therapy Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Male female patient &gt; /= 18 year age Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 At least 16 week life expectancy time entry study Histologically confirm metastatic colorectal cancer ( CRC ) Measureable , unresectable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) criteria version 1.1 No prior chemotherapy CRC metastatic setting Archival tumor formalinfixed paraffinembedded tissue block primary tumor obtain time initial diagnosis available Adequate hematological , liver renal function Agreement use highly effective measure contraception Less six month completion prior adjuvant chemotherapy , radiotherapy surgery Prior current treatment bevacizumab antiangiogenic drug ( i.e . VEGF vascular endothelial growth factor receptor [ VEGFR ] therapy tyrosine kinase inhibitor ) Current recent ( within 10 day study enrollment ) use aspirin ( &gt; 325 mg/day ) , clopidogrel ( &gt; 75 mg/day ) , current recent ( within 10 day prior start study induction treatment ) use therapeutic oral parenteral anticoagulant thrombolytic agent therapeutic purpose ( prophylactic us allow ) Active infection require intravenous antibiotic start study induction treatment Previous concurrent malignancy , except adequately treat basal squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree five year prior study entry Inadequately control hypertension ; prior history hypertensive crisis hypertensive encephalopathy Clinically significant ( i.e . active ) cardiovascular disease , example cerebrovascular accident &lt; /= 6 month prior start study induction treatment , myocardial infarction &lt; /= 6 month prior study enrollment , unstable angina , New York Heart Association ( NYHA ) Functional Classification Grade II great congestive heart failure , serious cardiac arrhythmia uncontrolled medication potentially interfere protocol treatment Significant vascular disease ( e.g . aortic aneurysm require surgical repair recent arterial thrombosis ) within 6 month start study induction treatment Active untreated CNS metastasis ; treatment brain metastasis , either surgical radiation technique , must complete &gt; 4 week prior start study induction treatment Known hypersensitivity component bevacizumab study medication Pregnancy lactation Archival primary tumor sample provide found include adequate quantity tumor tissue sufficient quality conduct biomarker test Cohort 1 BRAF ( mut ) Exclusion Criteria Inability swallow pill Refractory nausea vomiting , malabsorption , external biliary shunt significant bowel resection would preclude adequate absorption History presence clinically significant ventricular atrial dysrhythmias Corrected QT ( QTc ) interval &gt; /= 480 msec baseline history congenital long QT syndrome uncorrectable electrolyte abnormality Cohort 2 No Biomarker Exclusion Criteria History autoimmune disease include limited myasthenia gravis , myositis , autoimmune hepatitis , systemic lupus erythematosus , rheumatoid arthritis , inflammatory bowel disease , vascular thrombosis associate antiphospholipid syndrome , Wegener 's granulomatosis , Sjögren 's syndrome , GuillainBarré syndrome , multiple sclerosis , vasculitis , glomerulonephritis Prior allogeneic bone marrow transplantation prior solid organ transplantation History idiopathic pulmonary fibrosis ( include pneumonitis ) , druginduced pneumonitis , organize pneumonia , evidence active pneumonitis Screening Positive test human immunodeficiency virus ( HIV ) Active hepatitis B hepatitis C Screening Active tuberculosis Administration live , attenuate vaccine within four week prior start maintenance treatment anticipation live attenuate vaccine require remainder study Prior treatment CD137 agonist , antiCTLA4 , antiPD1 , antiPDL1 therapeutic antibody pathwaytargeting agent Treatment systemic immunostimulatory agent ( include limit interferon interleukin2 ) within four week five halflives drug , whichever short , prior start maintenance treatment Treatment systemic corticosteroid systemic immunosuppressive medication within 2 week prior start maintenance treatment , anticipated requirement systemic immunosuppressive medication remainder study . The use inhale corticosteroid mineralocorticoid allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>